Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN40,2240,29-3,93
Msft-2,84
Nokia3,533,5655-0,57
IBM-3,26
Daimler AG47,8947,895-0,90
PFE-0,68
26.10.2020 22:57:44
Indexy online
AD Index online
select
AD Index online
 

  • 28.09.2020 17:19:43
Bavarian Nordic (BAVA.F, Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
27,00 -0,17 -0,04 81
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.10.2020
Popis společnosti
Obecné informace
Název společnostiBavarian Nordic A/S
TickerBAVA
Kmenové akcie:Ordinary Shares
RICBAVA.CO
ISINDK0015998017
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 30.06.2020 604
Akcie v oběhu k 30.06.2020 58 413 532
MěnaDKK
Kontaktní informace
UliceHejreskovvej 10A
MěstoKVISTGAARD
PSČ3490
ZeměDenmark
Kontatní osobaRolf Soerensen
Funkce kontaktní osobyVice President Investor Relations & Communications
Kontatní telefon4 533 268 383

Business Summary: Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
Financial Summary: BRIEF: For the six months ended 30 June 2020, Bavarian Nordic A/S revenues increased from DKR228.2M to DKR1.06B. Net income totaled DKR625.9M vs. loss of DKR201.7M. Revenues reflect Sale of goods increase from DKR49M to DKR975.4M. Net Income reflects Research and Development Costs decrease of 37% to DKR124.1M (expense), Fair value adjustments on securities increase from DKR2.8M to DKR10.7M (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research



  • Poslední aktualizace: 26.10.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardGerard van Odijk6324.04.201424.04.2014
President, Chief Executive OfficerPaul Chaplin5328.05.2014
Independent Deputy Chairman of the BoardAnders Pedersen6924.04.201424.04.2014
Executive Vice President, Chief Financial OfficerHenrik Juuel5501.11.201801.11.2018
Executive Vice President, Chief Operating OfficerHenrik Birk4617.01.201717.01.2017
Executive Vice President, Chief Scientific OfficerLaurence De Moerlooze-
Executive Vice President, Chief Commercial OfficerJean-Christophe May53
Executive Vice President - People and OrganizationAnu Kerns-
Executive Vice President, Chief Business OfficerTommi Kainu4801.07.201701.07.2017